A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This study is seeking participants that have advanced or metastatic breast cancer (BC), or advanced or metastatic colorectal cancer (CRC). All participants in this study will take the study medication (PF-08032562) as pill by mouth. This will be repeated for 28-day cycles. Depending on which part of the study participants are enrolled into, they will receive the study medication PF-08032562 alone or in combination with other anti-cancer medications. The study medication (PF-08032562) will be taken by mouth (PO) in combination with other anti-cancer medications given in the study clinic by intramuscular (IM) injection into the muscle or intravenous (IV) infusion that is directly injected into the veins at different times (depending on the treatment) during the 28-day cycle. The study may also test different schedules.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Zaawansowany lub rozsiany rak piersi lub okrężnicy
- •Brak skutecznego leczenia standardowego lub progresja choroby mimo poprzedniego leczenia
- •Mierzalne ogniska choroby
- •Dobry ogólny stan zdrowia (ECOG 0-1)
✗ Disqualifies
- •Inne nowotwory złośliwe w ciągu ostatnich 3 lat
- •Przerzuty do mózgu powodujące objawy i wymagające sterydów
- •Zaawansowane przerzuty narządowe zagrażające życiu w krótkim okresie
- •Wcześniejsza radiacja powyżej 25% szpiku kostnego
- •Niekontrolowane wysokie ciśnienie krwi
- •Zaburzenia czynności nerek
- •Zaburzenia czynności wątroby
- •Zaburzenia rytmu serca lub struktura serca
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- May 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (9)
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, United States
START Midwest, LLC
Grand Rapids, United States
The University of Texas MD Anderson Cancer Center - Conroe
Conroe, United States
The University of Texas - M.D. Anderson Cancer Center
Houston, United States
The University of Texas, MD Anderson Cancer Center - West Houston
Houston, United States
The University of Texas, MD Anderson Cancer Center - League City
League City, United States
START San Antonio
San Antonio, United States
The University of Texas, MD Anderson Cancer Center - Sugar Land
Sugar Land, United States
START Mountain Region
West Valley City, United States
Trial contact
Pfizer CT.gov Call Center
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.